These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29987323)

  • 21. Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine".
    Giannelos N; Nishimwe ML; Lecrenier N
    Pharmacoeconomics; 2022 Oct; 40(10):1011-1012. PubMed ID: 36163540
    [No Abstract]   [Full Text] [Related]  

  • 22. [Vaccines against Herpes zoster: Effectiveness, safety, and cost/benefit ratio].
    Ferahta N; Achek I; Dubourg J; Lang PO
    Presse Med; 2016 Feb; 45(2):162-76. PubMed ID: 26724874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Authors' Reply to Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison Between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine".
    Bilcke J; Beutels P
    Pharmacoeconomics; 2022 Oct; 40(10):1013-1014. PubMed ID: 36163539
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(44):1528. PubMed ID: 22071592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How should nursing homes use vaccine to prevent zoster?
    Drinka PJ
    J Am Med Dir Assoc; 2007 Sep; 8(7):419-20. PubMed ID: 17845943
    [No Abstract]   [Full Text] [Related]  

  • 27. Shingles Vaccination Among Adults Aged 60 and Over: United States, 2018.
    Terlizzi EP; Black LI
    NCHS Data Brief; 2020 Jul; (370):1-8. PubMed ID: 32730737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine.
    Good CB; Hernandez I
    JAMA Intern Med; 2018 Jun; 178(6):873. PubMed ID: 29868745
    [No Abstract]   [Full Text] [Related]  

  • 29. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008.
    Lu PJ; Euler GL; Harpaz R
    Am J Prev Med; 2011 Feb; 40(2):e1-6. PubMed ID: 21238856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Varicella zoster virus redux.
    Gelb LD
    Herpes; 2009 Jan; 15(3):62-3. PubMed ID: 19306605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Herpes zoster subunit vaccine for the prevention of herpes zoster.
    Symoniak MR; Farrokh P; Gandhi MA; Slish JC
    Am J Health Syst Pharm; 2018 Jun; 75(12):861-869. PubMed ID: 29880523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of a herpes zoster vaccination program among the French elderly people.
    Belchior E; Lévy-Bruhl D; Le Strat Y; Herida M
    Hum Vaccin Immunother; 2016 Sep; 12(9):2378-82. PubMed ID: 27484158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia.
    Brisson M; Pellissier JM; Levin MJ
    Clin Infect Dis; 2007 Dec; 45(11):1527-9. PubMed ID: 17990240
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zoster vaccine live.
    Kockler DR; McCarthy MW
    Pharmacotherapy; 2007 Jul; 27(7):1013-9. PubMed ID: 17594207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
    Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
    Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interpretation of results of the cost-effectiveness analysis reported by Pellissier et al. on October 2007.
    Najafzadeh M; Sadatsafavi M; Marra CA
    Vaccine; 2008 Sep; 26(41):5244; author reply 5245. PubMed ID: 18619510
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
    Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P
    Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Commentary regarding: Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. H Lal, AL Cunningham, O Godeaux et al., N Engl J Med 372:2087-2096, 2015.
    Yancey KB
    Dermatol Ther; 2016 Sep; 29(5):300-301. PubMed ID: 26798973
    [No Abstract]   [Full Text] [Related]  

  • 40. Q: Who should receive the shingles vaccine?
    Singh A; Englund K
    Cleve Clin J Med; 2009 Jan; 76(1):45-8. PubMed ID: 19122110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.